Working to Improve Eosinophilic Esophagitis (EoE) Treatment

If you or someone you know has been diagnosed with EoE, you may be interested in enrolling in a clinical trial studying a new treatment option.



Have on average trouble swallowing food at least twice a week

Digestive system

Must be on a stable diet and medications for EoE

18 - 75

Participants must be age 18 to 75 years old, both inclusive


Documented diagnosis of EoE

Additional criteria will need to be met and will be discussed with a doctor.

Why participate?

Clinical trials help physicians and researchers learn more about EoE and new medications that may help patients like yourself.*

If you are eligible to participate, you will receive:
• Expert medical care related to the study, at no cost to you
• Compensation for travel and inconvenience

* The study medication is investigational, which means that it is not approved by the FDA.

Revolo Clouds

What is the purpose of the clinical trial?

The purpose of this research study is to learn about how people diagnosed with EoE respond to IRL201104 (‘1104 – “the study medication”), and if the study medication will help with their symptoms.

During the trial, ‘1104 will be given once a week for two weeks after your first dose. An endoscopy and biopsy will be performed once before your first dose and once after the last dose.

Frequently Asked Questions

Before any medication can be approved for public use, it must go through several phases of clinical trials to make sure that it is safe and effective. Clinical trials are controlled studies evaluating investigational drugs in humans. To participate in a clinical trial, you must meet all eligibility criteria and be willing to follow the directions of the study doctor. A team of doctors, nurses and trial coordinators will be working closely with you throughout the trial to monitor any symptoms or changes and ensure you remain comfortable and informed.

Reasonable compensation for travel and inconvenience will be provided. All study drugs will be provided to you at no cost.

You may respond to the study treatment, but we cannot be certain it will be effective. The study treatment may reduce the symptoms of EoE. For example, you may experience less chest pain, find it easier to swallow, and be less likely to get food stuck in the throat or to regurgitate or vomit. There is no guarantee that you will experience any benefits from this study.

To learn more, see study locations in the map below or complete the contact form below.

See below for a map of our current trial sites. We will update the map as sites are added. If you do not see a trial location near you, please complete the form below and we will keep you updated.

Study Locations

If you are unable to find a location near you, be sure to check back soon as we are regularly adding study locations.

      Active location

      Coming soon

      Contact Us

      Scroll to Top

      Tunde Otulana, M.D.

      Non-Executive Director

      Tunde is currently the Chief Medical Officer of Veloxis Pharmaceuticals in North Carolina, USA since August 2020. Prior to Veloxis he was Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals. His career, which spans about 30 years in industry, government and academia, includes leadership roles at Boehringer Ingelheim Pharmaceutical Inc. and the US Food and Drug Administration (“FDA”). Tunde is a physician trained in Pulmonary and Critical Care Medicine.

      Beth Alley

      VP of Regulatory Affairs

      Beth Alley has over 20 years of experience within the biopharmaceutical industry in regulatory affairs, commercial strategy, and medical writing throughout all phases of drug development. Her primary areas of focus have been in development of biologics for treatment of autoimmune, inflammatory, and infectious diseases.

      Glen Giovanetti

      Non-Executive Director

      Glen Giovanetti has more than 35 years of experience in strategy and operational leadership in the life science industry as well as in financial governance, risk and reporting as EY’s Global Biotechnology Sector Leader and Life Sciences Sector Leader. He currently serves on the Board of Directors of Life Science Cares, Teon Therapeutics and XW Pharma.

      Marla S. Persky

      Non-Executive Director

      Marla S. Persky currently serves as the chief executive officer and president of WOMN LLC. She has more than 25 years of international senior business and legal experience in the pharmaceutical industry having held numerous business and legal positions at Boehringer Ingelheim and Baxter International. She currently serves on the Boards of Directors of Xeris Pharmaceuticals, YGEIA Consulting Group, Primary Stages, World Neighbors and A Better Chance in Ridgefield.

      Dora Rau

      Senior Vice President, Quality

      Dora Rau brings 25 years of experience in development and commercial operations for drugs, biologics, devices and combination products to the team. She has held numerous executive-level quality positions, with expertise in building quality systems and in leading teams to attain successful regulatory authority inspection outcomes and product approvals.

      Jonathan Gold

      Chief Financial Officer

      Over the last 25 years, Jonathan Gold has been an institutional venture capitalist, a public fund manager, a founder, an operating executive, and a board member for companies across sectors including life sciences. In those roles, he was active in the development, financing and mergers and acquisitions for numerous public and private companies.

      Team Members

      Michael Albisser

      Non-Executive Director​

      Michael is a partner of Metellus, a Zurich and London-based venture capital firm investing in technology and life sciences with ground-breaking potential. Having more than 25 years of experience in the finance area he is responsible for finance, tax, and deal structures. He serves on the board of various venture-backed companies.

      Dr. Isaac Cheng, m.d.

      Non-Executive Director

      Dr. Isaac Cheng is currently an investment professional at Morningside, a venture capital and private equity institution based in Boston USA, and Shanghai China. Dr. Cheng focuses primarily on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards.

      Peter Greenleaf


      Peter Greenleaf currently serves as the chief executive officer (CEO) and member of the Board of Directors of Aurinia, (NASDAQ: AUPH / TSX: AUP), an autoimmune therapeutics company. He has held several other CEO and chairman roles. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI).

      Marylyn Rigby

      VP of Marketing and Investor Relations

      Marylyn Rigby is an experienced pharmaceutical, biotech, and drug delivery professional. In addition to her expertise in marketing, public and investor relations, she has a successful track record with business development, licensing, public and private equity financing, strategy and other key corporate functions.

      Nancy Vinh

      VP of Clinical Operations

      Nancy Vinh brings over 20 years of experience in managing early and late phase, international clinical trials for drugs, biologics, cell therapy and combination products across a wide range of therapeutic areas to the team. She has served as head of clinical operations and led registrational and label expansion trials execution.

      Team Members

      Dr. Clare Burgess

      Chief Development Officer

      Dr. Clare Burgess has 24 years of experience in clinical drug development as a pharmacologist and has worked across a wide range of therapeutic areas within the pharmaceutical industry. She has held multiple leadership roles and has led multidisciplinary teams across the world.

      Jeff Myers, m.d., ph.d

      Chief Medical Officer

      Jeff Myers, M.D., Ph.D., has 20 years of experience in medical affairs, regulatory and clinical development within the biopharmaceutical industry, with focuses on cardiovascular, pulmonary, oncology, and inflammatory diseases.

      Before entering the industry, he practiced as a congenital cardiac surgeon and served as the chief of pediatric cardiac surgery at Massachusetts General Hospital and as Associate Professor of Surgery at Harvard Medical School.

      Team Members

      Dr. Roly Foulkes

      Chief Scientific Officer

      A true drug discoverer, Dr. Roly Foulkes has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.

      Team Members

      Jones w (woody) Bryan, ph.d.

      President & Chief Business Officer

      Jones (Woody) Bryan, Ph.D., brings almost 30 years of experience in the healthcare industry to the team, having led successful business development operations in both private and public pharma and biotech companies.

      Team Members

      Jonathan Rigby, mba

      Group Chief Executive Officer

      As employee #1 of Revolo Biotherapeutics in the US, Jonathan Rigby has led the company through substantial and rapid growth. He brings three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry.

      Team Members
      • Carrie Vincent: Director, HR & Senior Executive Administration
      • Dr. Jones W. (Woody) Bryan: Chief Business Officer
      • Dr. Roly Foulkes: Chief Scientific Officer
      • Jonathan Gold: Chief Financial Officer
      • Jeff Myers, MD: Chief Medical Officer
      • Marylyn Rigby: VP Marketing & Investor Relations
      • Dr. Perry Calias: Chief Operating Officer